Release Date: 23-Jan-2025
BI 836880, developed by Boehringer Ingelheim, is a humanized bispecific nanobody designed to target two critical pathways involved in tumor growth and angiogenesis: vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANG2). This innovative molecule consists of two single-variable domains that specifically block VEGF-A and ANG2, along with an additional module that extends its half-life in vivo, enabling prolonged therapeutic activity. The dual targeting approach of BI 836880 allows for a comprehensive inhibition of the VEGF and ANG2 signaling pathways, which are crucial in promoting endothelial cell proliferation, survival, and the formation of new blood vessels that support tumor growth.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
Preclinical studies have demonstrated that BI 836880 exhibits high affinity and selectivity for both VEGF-A and ANG2, effectively blocking their downstream signaling. This blockade results in a significant reduction in endothelial cell proliferation and survival, crucial factors that contribute to tumor vascularization and growth. In patient-derived xenograft models, BI 836880 showed impressive antitumor activity, achieving significantly greater tumor growth inhibition (TGI) than both bevacizumab (which inhibits VEGF) and AMG386 (which inhibits ANG1/2). These results suggest that the dual blockade of VEGF and ANG2 with BI 836880 may offer superior antitumor activity compared to targeting either pathway alone.
Moreover, combining VEGF/ANG2 inhibition with PD-1 blockade has been shown to further enhance antitumor effects. This combination approach is particularly promising, as it targets both the tumor vasculature and the immune checkpoint pathway, potentially boosting the immune system’s ability to recognize and destroy cancer cells. BI 836880 is currently being evaluated in Phase 2 clinical trials for Anal Canal Squamous Cell Carcinoma, in combination with BI 754091, an anti-PD-1 antibody. The ongoing trials aim to assess the therapeutic potential of this combination in treating patients with this challenging cancer, building on the preclinical promise of enhanced efficacy through dual pathway inhibition and immune modulation.